Roquefort Therapeutics (LSE:ROQ) Cash And Cash Equivalents : £0.54 Mil (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Roquefort Therapeutics Cash And Cash Equivalents?

Roquefort Therapeutics's quarterly cash and cash equivalents declined from Dec. 2022 (£2.32 Mil) to Jun. 2023 (£1.38 Mil) but then stayed the same from Jun. 2023 (£1.38 Mil) to Dec. 2023 (£0.54 Mil).

Roquefort Therapeutics's annual cash and cash equivalents increased from Dec. 2021 (£0.90 Mil) to Dec. 2022 (£2.32 Mil) but then declined from Dec. 2022 (£2.32 Mil) to Dec. 2023 (£0.54 Mil).

Roquefort Therapeutics Cash And Cash Equivalents Historical Data

The historical data trend for Roquefort Therapeutics's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Roquefort Therapeutics Cash And Cash Equivalents Chart

Roquefort Therapeutics Annual Data

Trend

Dec21

Dec22

Dec23

Cash And Cash Equivalents

0.90

2.32

0.54

Roquefort Therapeutics Semi-Annual Data
	Jun21	Jun22	Dec22	Jun23	Dec23
Cash And Cash Equivalents	0.88	3.33	2.32	1.38	0.54

Roquefort Therapeutics Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Roquefort Therapeutics (LSE:ROQ) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

Roquefort Therapeutics Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Roquefort Therapeutics's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

Roquefort Therapeutics (LSE:ROQ) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Roquefort Therapeutics PLC (LSE:ROQ) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

ROQAF:USA

Address

85 Great Portland Street, First Floor, London, GBR, W1W 7LT

Website

https://www.roquefortplc.com

Roquefort Therapeutics PLC is engaged in pursuing opportunities to acquire medical biotechnology businesses that are at an early stage in the medical sector including Drug and vaccine development; Diagnostics; Immuno-therapy; and Cell and gene therapies. The principal activity of the Company is to develop pre-clinical next generation medicines focused on hard to treat cancers.

Roquefort Therapeutics (LSE:ROQ) Headlines

No Headlines